Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.53 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339364 | 0.81 | IKBKE (0.38) | IKBKEJAK2MAPTTP53 | |
| SCHEMBL8888245 | 0.80 | POLB (0.58) | IDO1NOTUMMAPTMEN1LMNA | |
| SCHEMBL28025294 | 0.80 | POLB (0.48) | JAK2MAPTTP53LMNA | |
| SCHEMBL474802 | 0.79 | ALPL (0.54) | NOTUMMAPTTP53MEN1LMNA | |
| SCHEMBL8005401 | 0.79 | POLB (0.53) | IDO1IKBKEJAK2MAPTMEN1 | |
| SCHEMBL15425114 | 0.79 | POLB (0.49) | IDO1IKBKEJAK2NOTUMMAPT | |
| SCHEMBL15425079 | 0.79 | POLB (0.49) | IDO1IKBKEJAK2NOTUMMAPT | |
| SCHEMBL168659 | 0.79 | POLB (0.61) | TP53LMNA | |
| SCHEMBL14726245 | 0.79 | IDO1 (0.53) | IDO1NOTUMMAP4K4MAPTTP53 | |
| SCHEMBL168536 | 0.79 | MAPT (0.54) | IDO1NOTUMMAP4K4MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-8633200-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633200-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633200-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2614064-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-06 | — | — | US | disclosed |
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-06 | — | — | US | disclosed |
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-06 | — | — | US | disclosed |
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | Sanford-Burnham Medical Research Institute California | 2012-04-19 | — | — | US | disclosed |
| EP-2433496-A1 | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification | Burnham Institute for Medical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2164329-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | The Burnham Institute for Medical Research (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | disclosed |
| WO-2009017863-A2 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-05 | — | — | WO | disclosed |
| US-7473783-B2 | Bicyclic pyrazolo protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1713814-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050176786-A1 | Bicyclic pyrazolo protein kinase modulators | STRUCTURAL GENOMIX (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005068473-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| US-6649759-B2 | Pyrazolo(1,5-a)pyrimidine derivatives; treating feeding, cardiovascular and psychological disorders | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030100546-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2003-05-29 | — | — | US | disclosed |
| US-20020061897-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100546-A1 | Neuropeptide Y antagonists | NPY1R, NPY2R, GIPR | IDO1 1326/4885IKBKE 2138/4885JAK2 706/4885 |
| US-20050176786-A1 | Bicyclic pyrazolo protein kinase modulators | MAP3K20, MAP4K2, MAP4K3 | IDO1 3282/4885IKBKE 393/4885JAK2 408/4885 |
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | IDO1 583/4885IKBKE 437/4885JAK2 2822/4885 |
| US-20120095044-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | IDO1 2242/4885IKBKE 1709/4885JAK2 2641/4885 |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | IDO1 2242/4885IKBKE 1709/4885JAK2 2641/4885 |
| US-20020061897-A1 | Neuropeptide Y antagonists | NPY1R, NPY2R, GIPR | IDO1 1326/4885IKBKE 2138/4885JAK2 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.